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Background and Aims: In recent years, mesenchymal stromal cells [MSCs] emerged as a 
promising therapeutic option for various diseases, due to their immunomodulatory properties. 
We previously observed that intraperitoneally injected MSCs in experimental colitis form spherical 
shaped aggregates. Therefore, we aggregated MSCs in vitro into spheroids and injected them 
intraluminally in mice with established colitis, to investigate whether these MSC spheroids could 
alleviate the colitis.
Methods: We injected 0.5 x 106 MSCs in spheroids, 2.0 x 106 MSCs in spheroids, or phosphate-
buffered saline [PBS] as a treatment control, via an enema in mice with established dextran 
sulphate sodium [DSS]-induced colitis. Body weight was measured daily and disease activity 
score was determined at sacrifice. Endoscopy was performed to evaluate mucosal healing. After 
sacrifice, both systemic and local inflammatory responses were evaluated.
Results: Intraluminally injected MSC spheroids alleviated DSS-induced colitis, resulting in 
significantly less body weight loss and lower disease activity score at sacrifice when a high dose of 
MSC spheroids was administered. However, the percentage of mucosal lesions in the distal colon 
and endoscopy scores were not significantly lower after treatment with 2.0 x 106 MSCs in spheroids 
compared with PBS-treated mice. Systemic inflammation marker serum amyloid A  [SAA] was 
significantly reduced after treatment with 2.0 x 106 MSCs in spheroids. In addition, local cytokine 
levels of IFN-ɣ, TNF-α, IL-6, and IL-17a, as well as numbers of macrophages and neutrophils, showed 
a clear decrease—though not always significant—after intraluminal injection of the MSC spheroids.
Conclusion: Intraluminally injected MSC spheroids at least partially attenuate experimental colitis, 
with fewer phagocytes and proinflammmatory cytokines, when a high dose of MSCs in spheroids 
was administered.
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1. Introduction
Due to their immunomodulatory properties and their ability to 
actively participate in tissue repair, mesenchymal stromal cells 
[MSCs] have emerged as a potential therapeutic alternative in the 
treatment of several diseases.1 Promising reports on the use of MSCs 
as a treatment for both experimental colitis and human inflam-
matory bowel disease [IBD] have been published in the past few 
years.2,3,4,5,6 Currently, their exact mode of action is under investiga-
tion. Previously it became clear that MSC therapy is not beneficial 
under all conditions of an ongoing immune response, and that the 
timing of administration is important to induce the full immuno-
suppressive and tissue regenerative properties of MSCs.7 In recent 
years, potentiating the therapeutic efficacy of MSCs by priming with 
proinflammatory cytokines such as interferon-gamma [IFN-ɣ] and/
or tumour necrosis factor alpha [TNF-α] to create an immunostimu-
latory milieu in vitro before use in vivo was also evaluated.8, 9
Although encouraging results have been obtained in different 
preclinical studies using these primed MSCs,10,11 caution should be 
taken as MSCs can participate in antigen presentation by upregu-
lation of major histocompatibility [MHC] class  II molecules when 
not primed sufficiently. This could finally result in a potential risk 
of rejection and exaggeration of an ongoing immune response, ulti-
mately worsening the disease.7,12,13,14,15 Therefore, new methods to 
increase the immunomodulatory effects of MSCs should be assessed.
Recently, intraperitoneally injected MSCs were observed to clus-
ter together to form aggregates which produced the anti-inflamma-
tory protein tumour necrosis factor-inducible gene [TSG]-6 leading 
to attenuated dextran sulphate sodium [DSS]-induced colitis.16 
Remarkably, intravenously injected MSCs in experimental myo-
cardial infarction, entrapped within the lungs, also formed clusters 
that produced TSG-6—thereby improving tissue damage.17 In our 
previously performed experiments, we also observed that intraperi-
toneally injected MSCs form spherical shaped aggregates. To inves-
tigate whether MSCs aggregated into spherical clusters, ie spheroids, 
could alleviate experimental colitis, we created MSC spheroids in 
vitro and injected them in mice with established DSS-induced coli-
tis. Since the inflammation is in the mucosa of the distal colon, we 
injected the MSC spheroids intraluminally via an enema, hypothesis-
ing that MSC spheroids might integrate into the mucosa or release 
soluble factors which contribute to the attenuation of experimental 
colitis. We observed that intraluminal injection of in vitro-generated 
MSC spheroids alleviated DSS-induced colitis when given in a high 
dose, which was accompanied by a decreased invasion of distinct 
immune cells and a reduced mucosal production of some proinflam-
matory cytokines.
2. Material and Methods
2.1. MSC isolation
Murine bone marrow MSCs were isolated from 8 to 12-week-old 
C57BL/6Jico mice [Charles River Maastricht, The Netherlands]. 
Mice were sacrificed by cervical dislocation and femurs and tibiae 
were removed, cleaned of tissue, and flushed to retrieve bone marrow 
cells. Cells were plated in αMEM [Lonza, Verviers, Belgium] sup-
plemented with 10% fetal calf serum [Hyclone, Thermo Scientific, 
Landsmeer, The Netherlands], 3mM L-glutamine [Invitrogen, 
Bleiswijk, The Netherlands], and penicillin/streptomycin [Lonza, 
Verviers, Belgium] after a centrifugation step, and expanded in a 
37°C humidified incubator containing 5% CO2. After 24 h, non-
adherent cells were removed and the medium was refreshed every 
3–4  days. The protocol for the experiments was approved by the 
Committee on Animal Welfare of the Leiden University Medical 
Center.
2.2. MSC spheroid formation
Spheroids were formed in 96-well culture plates [Greiner Bio-One 
BV, Alphen a/d Rijn, The Netherlands] of 2500 MSCs per well. Thus, 
every spheroid consisted of 2500 MSCs and 0.24% methyl cellulose 
[Sigma-Aldrich Chemie BV, Zwijndrecht, The Netherlands] which 
was added to the medium in each well to enhance spheroid forma-
tion. MSCs from passages 6 to 8 were used to create spheroids for 
transplantation experiments. Spheroids were harvested after 2 days 
of culture. Before in vivo injection, MSC spheroids were thoroughly 
washed with PBS. Either 0.5 x 106 or 2.0 x 106 MSCs in spheroids 
were injected locally, meaning 200 spheroids consisting of 2500 
MSCs per spheroid in case of 0.5 x 106 MSCs in spheroids, and 800 
spheroids consisting of 2500 MSCs per spheroid in case of 2.0 x 106 
MSCs in spheroids.
In indicated in vitro experiments, 500 U/ml recombinant mouse 
IL-6 [Life Technologies, Bleiswijk, The Netherlands] or recombinant 
mouse TNF-α [R&D systems, Abingdon, UK] was added to each 
well at Day 1. In these experiments, in total 12-15 96-well culture 
plates per time point were used to generate spheroids, resulting in 
1152–1440 spheroids per time point.
2.3. MSC characterisation
Immunophenotyping of MSCs was performed using the following 
primary antibodies: CD44, CD105, CD106 [BD Biosciences, San 
Diego, CA, USA], CD29, Sca-1, and CD45 [eBioscience, Vienna, 
Austria]. Samples were analysed using a FACSCanto II flow cytom-
eter with Diva Software [BD Biosciences, San Diego, CA, USA] and 
the data were analysed with FlowJo software [version 8.7.1., Tree 
Star Inc. Ashland, OR, USA]. In vitro differentiation was performed 
in 24-well culture plates with MSCs at 80% confluency. MSC sphe-
roids were transferred to 24-well plates after 2 days of culture and 
4  days before the start of differentiation. For osteogenic differen-
tiation, MSCs and spheroids were stimulated for 21 days in com-
plete medium supplemented with 10–8 M dexamethasone, 50  μg/
ml ascorbic acid, and 10 mM β-glycerophosphate [all from Sigma-
Aldrich Chemie BV, Zwijndrecht, The Netherlands]. Alkaline phos-
phatase activity was shown with Fast Blue, and calcium deposit with 
Alizarin Red [both Sigma-Aldrich Chemie BV, Zwijndrecht, The 
Netherlands]. For adipogenic differentiation, MSCs and spheroids 
were stimulated for 21 days in adipogenic differentiation medium 
consisting of complete medium supplemented with dexamethasone 
[10–6 M], insulin [5 µM], indomethacin [100 μM], and 3-isobutyl-
1-methylxanthine [0.5 mM] [all from Sigma-Aldrich Chemie BV, 
Zwijndrecht, The Netherlands]. Formation of lipid droplets was 
visualised with Oil-red O staining [Sigma-Aldrich Chemie BV, 
Zwijndrecht, The Netherlands].
2.4. Induction of colitis and intraluminal injection 
of MSCs
Animals were housed in individually ventilated cages and were given 
drinking water and food ad libitum. Colitis was induced in 8-week-
old female C57BL/6Jico mice [Charles River Laboratories, The 
Netherlands] with 1.25% dextran sulphate sodium [DSS; MW 36 
000–50 000 kDA; MP Biomedicals, Illkirch, France] supplied in the 
drinking water for 7 days. Five days after the introduction of DSS, 
mice received locally (with a 22 gauge catheter [Abbocath, Hospira 
Benelux, Brussels, Belgium] approximately 3 cm from the anus) 0.5 x 
106 or 2.0 x 106 MSCs in spheroids in 150 µl PBS [n = 7 and n = 14, 
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respectively], or PBS alone [n = 7] as a treatment control. The healthy 
control group consisted of three mice that received 2.0 x 106 MSCs 
in spheroids [‘normal’ group]. In Supplementary Figure 1 [available 
as Supplementary data at ECCO-JCC online] the results of healthy 
control groups that received 0.5 x 106 MSCs in spheroids [n = 3], 
PBS [n  =  3], or without treatment [n  =  3] are shown. Mice were 
anaesthetised with isoflurane and kept upside down for 5 min after 
injection. Mice were sacrificed 10 days after the start of the experi-
ment. The separate endoscopy study consisted of 10 mice with DSS-
induced colitis treated with 2.0 x 106 MSCs in spheroids and 9 mice 
treated with PBS. These mice were sacrificed 12 days after the start 
of the experiment, to be able to evaluate mucosal healing.
2.5. Assessment of disease activity
Body weight was measured daily and disease progression and 
recovery were calculated as a percentage of weight loss from body 
weight at the start of the experiment. Furthermore, endoscopy was 
performed with the Coloview mini-endoscopic system of Karl Storz 
[Stöpler, Utrecht, The Netherlands]18 at Days 0, 5, 8, 10, and 12 to 
evaluate mucosal damage and subsequent healing. The murine endo-
scopic index of colitis severity [MEICS] was used to quantify the 
thickening of the colon, changes of the vascular pattern, fibrin depo-
sition, granularity of the mucosal surface, and stool consistency.18 
MEICS was scored blindly and independently by two researchers. At 
sacrifice, blood was collected by cardiac puncture and centrifuged 
[10 000g for 10 min] to collect serum which was stored at -20°C. 
Colon length was measured, as an indicator of disease-related intes-
tinal shortening, and colons were opened longitudinally to calculate 
the disease activity score consisting of the presence of loose stool, 
visible fecal blood, and macroscopic inflammation, using a scale 
of 0–3 per item resulting in a maximum score of 9.19 Colons were 
either stored in 4% neutral buffered formalin as a ‘swiss roll’20 and 
embedded in paraffin for [immuno]histological evaluation, or the 
distal part of the colon was directly frozen in isopentane for protein 
extraction and cytokine measurements.
2.6. Histological evaluation of disease activity
The paraffin-embedded colons were cut into sections of 4 µm and 
stained with haematoxylin and eosin [HE] to evaluate the number 
of lesions in the distal 3 cm of the colon where DSS-induced coli-
tis is most pronounced. A lesion was defined as a part of the colon 
without epithelium. Colon- and lesion-lengths were measured with 
Olympus CellSens [version 1.7.1, Zoeterwoude, The Netherlands]. 
All colons were measured twice, and the researcher was blind to 
the treatment mice had received. The average percentage of mucosal 
lesions is shown in Figure 2F.
2.7. Immunohistochemistry
Apoptosis was shown in MSCs and MSC spheroids embedded in par-
affin with an anti-cleaved caspase-3 antibody [1:800, Cell Signaling, 
Leiden, The Netherlands]. Macrophages were detected with an anti-
F4/80 antibody [1:800, eBioscience Ltd, Hatfield, UK] and T regula-
tory cells [Tregs] with an anti-FoxP3 antibody [1:500, eBioscience 
Ltd, Hatfield, UK]. In brief, slides were deparaffinised, hydrated, 
and incubated in 0.3% H2O2/methanol for 20 min at room tempera-
ture. Slides were blocked with Teng-T [10 mM Tris, 5 mM EDTA, 
0.15 M NaCl, 0.25% gelatin, 0.05% [v/v] Tween-20, pH 8.0] for 
30 min or with proteinase K [50 µg/ml] for 10 min at 37°C, and sub-
sequently incubated overnight at 4°C with primary antibody in PBS 
containing 0.1% TritonX-100 and 1% bovine serum albumin [BSA] 
and followed by a peroxidase-labelled polymer [EnVision+, Dako 
Netherlands BV, Heverlee, Belgium]. For staining of macrophages 
and Tregs, slides were incubated for 1 [at room temperature] with 
a rabbit anti-rat HRP secondary antibody conjugated secondary 
antibody [1:200, Dako Netherlands BV, Heverlee, Belgium] diluted 
in PBS containing 0.01% TritonX-100 and 1% BSA, instead of a 
peroxidase-labelled polymer. Peroxidase activity was detected with 
3,3’-diaminobenzidine tablets [DAB Fast Tablet, Sigma-Aldrich, St 
Louis, MO, USA]. Sections were counterstained with haematoxylin, 
dehydrated, and mounted in Entellan [Merck KGaA, Darmstadt, 
Germany]. Microscopic images of the distal 3 cm of the colon were 
made with a magnification of x 20. The F4/80-positive cells in these 
slides were counted using ImageJ software [version 1.45s, National 
Institutes of Health, USA] to quantify their number in the mucosa of 
the distal 3 cm of the colon.
2.8. Serum amyloid A and cytokine measurements
Serum amyloid A  [SAA] levels were measured in the serum col-
lected upon sacrifice, using a solid phase sandwich ELISA kit [Life 
Technologies, Bleiswijk, The Netherlands].
Homogenates were prepared from distal colon with a Potter-
Elvehjem glass homogeniser at 4°C in Greenberger lysis buffer 
[150 mM NaCl, 15 mM Tris, pH 7.4, 1 mM MgCl2, and 1% 
TritonX-100]. Samples were centrifuged for 15 min [11 000g at 4°C] 
and stored at -80°C. The BCA Protein Assay Kit [Thermo Scientific 
Pierce, Etten-Leur, The Netherlands] was used to determine the total 
concentration of protein in the colons and cytokine levels of IFN-ɣ, 
IL-2, IL-4, IL-6, IL-10, IL-17a, and TNF-α were measured using 
the Cytometric Bead Array System [BD Biosciences, San Diego, CA, 
USA] following the manufacturer’s instructions. Data were analysed 
with FlowJo software [version 8.7.1., Tree Star Inc. Ashland, OR, 
USA]. Cytokine levels measured were corrected for the amount of 
total protein.
2.9. MPO determination
Myeloperoxidase [MPO] activity in the homogenates of distal 
colon was measured as an index for neutrophil infiltration. In brief, 
homogenates were sonicated and 0.5% hexadecyltrimethylammo-
nium bromide [HTAB, Sigma-Aldrich Chemie BV, Zwijndrecht, The 
Netherlands] in 50 mM in phosphate buffer [pH 5.5] was added to 
the sonicated homogenates and incubated for 30 min at room tem-
perature. Supernatants were mixed with 150 µl of phosphate buffer 
[pH 5.5; 37°C] containing 0.26 mg/ml o-dianisidine dihydrochlo-
ride [Sigma-Aldrich Chemie BV, Zwijndrecht, The Netherlands] and 
0.52 mM 30% H2O2. Colorimetric reaction was measured at 450 nm 
for 30 min using a spectrophotometer; 1 µmol H2O2 [ = 1 unit of 
MPO] split gives a change in absorbance of 1.13 x 10-2/min. The 
number of MPO units was determined as ΔA450/[Δtime x 1.13 x 10
-2] 
and corrected for the total amount of protein per sample. Samples 
were analysed in duplicate.
2.10. RNA isolation and quantitative PCR
RNA from distal colons after sacrifice and from MSC spheroids 1 to 
5 days after the start of culture [n = 1152–1440 spheroids per time 
point] was extracted using RNeasy Mini Kit [Qiagen] according 
to the manufacturer’s instructions. cDNA synthesis was performed 
using RevertAid reverse transcriptase [Fermentas, St. Leon-Rot, 
Germany] and random primers [Promega, Leiden, The Netherlands]. 
Quantitative polymerase chain reaction [PCR] using SYBR green 
[QuantiFast SYBR Green PCR Kit, Qiagen] with a forward and 
reverse primer mix for COX-2 [NM_011198] [QuantiTect Primer 
Assay, Qiagen] was performed. The household gene glyceraldehyde 
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3-phosphate dehydrogenase [GAPDH, QiantiTect Primer Assay, 
Qiagen] was used to normalise the data. Samples were analysed in 
triplicate.
2.11. PGE2 ELISA
Prostaglandin E2 [PGE2] was measured in the homogenates of the 
distal colons at sacrifice and in the supernatants of MSC spheroids 
1 to 5 days after the start of culture, using a competitive enzyme-
linked immunosorbent assay [ELISA] kit [Abcam, Cambridge, UK] 
following the manufacturer’s instructions. Samples were analysed in 
duplicate.
2.12. Statistical Analysis
To compare two groups, parametric or non-parametric analyses 
were performed using an unpaired Student’s t test or Mann-Whitney 
U test, respectively. Numerical values were expressed as means ± 
standard error of the mean [SEM]. All analyses were performed using 
GraphPad Prism software [GraphPad Software, version 5.01, San 
Diego, CA]; P-values ≤ 0.05 were considered statistically significant.
3. Results
3.1. Intraluminally injected MSC spheroids alleviate 
DSS-induced colitis
The in vitro generated MSC spheroids had an average size of 
148.9 ± 3.8 µm [n  = 6], a low expression of the apoptotic marker 
cleaved caspase-3 [Figure 1A, right panel], and every spheroid was 
constructed from 2 500 by flow cytometry characterising single cell 
MSCs [Figure 1B]. Similarly to single cell MSCs, MSC spheroids were 
able to differentiate into adipocytes and osteoblasts [Figure 1C].
Subsequently, we examined whether our in vitro generated 
MSC spheroids could attenuate DSS-induced colitis. Mice received 
either 0.5 x 106 or 2.0 x 106 MSCs in spheroids intraluminally via 
an enema at Day 5, when colitis was established. Treatment with 
2.0 x 1 06 MSCs in spheroids resulted in significantly reduced body 
weight loss at sacrifice compared with treatment with 0.5 x 1 06 
MSCs in spheroids or PBS [9.2% vs 16.4% and 15.9%, respectively; 
both p = 0.02; Figure 2A]. Moreover, disease-related shortening of 
the colon was significantly reduced after treatment with 2.0 x 106 
MSCs in spheroids compared with PBS [p  <  0.05; Figure  2B and 
C], which was also reflected in the macroscopic disease activity 
score consisting of the presence of loose stool, visible fecal blood, 
and macroscopic inflammation at sacrifice [p = 0.01 compared with 
PBS; Figure  2D]. In addition, histological evaluation of the distal 
colon revealed a clear but non-significant trend towards less mucosal 
lesions by injection with 2.0 x 106 MSCs in spheroids compared with 
PBS [Figure 2E and F].
To quantify mucosal damage during the colitis, a second experi-
ment was performed. Mice were treated with 2.0 x 106 MSCs in sphe-
roids or PBS at Day 5 when colitis was established and endoscopy 
was performed at Days 0, 5, 8, 10, and 12 [Figure 3A]. The MEICS 
score was calculated to quantify the thickening of the colon, changes 
of the vascular pattern, fibrin deposition, granularity of the mucosal 
surface, and stool consistency. The endoscope could be inserted in 
the colon up to approximately 3–4 cm from the anus. At day 0, 
endoscopy showed a smooth and translucent mucosal surface with 
a normal blood vessel architecture and solid stools, as DSS was not 
yet introduced in the drinking water, resulting in a MEICS score of 0 
[Figure 3B]. Five days after the start of DSS, the colon transparency 
was reduced and the mucosa was vulnerable, which in some mice 
resulted in bleedings. At Day 8, signs of severe inflammation were 
present. Mice presented with diarrhoea and non-transparent mucosa 
with moderate granularity and some fibrin deposition. The highest 
MEICS score was reached at Day 10. At Day 12, treatment with 2.0 
x 106 MSCs in spheroids seemed to partially reduce the MEICS score 
compared with PBS-treated mice [Figure 3B]. Body weight, disease 
activity, and colonic TNF-α, IFN-ɣ, IL-6, and IL-17a at Day 12 are 
shown in Supplementary Figure 2 [available as Supplementary data 
at ECCO-JCC online].
3.2. Local treatment with MSC spheroids results in 
reduction of some inflammatory mediators
The systemic marker of inflammation SAA was drastically upregu-
lated when DSS was induced, indicating a severe colitis [Figure 4A]. 
Intraluminal treatment with 2.0 x 106 MSCs in spheroids resulted 
in a significant reduction of SAA in the serum at sacrifice compared 
with PBS treated mice [p = 0.04; Figure 4A]. Locally the number of 
neutrophils, as reflected by MPO activity, was significantly lower in 
the distal colons of mice treated with 2.0 x 106 MSCs in spheroids 
compared with PBS [p = 0.03; Figure 4B]. In addition, lower num-
bers of macrophages were observed in the distal colon after MSC 
spheroids treatment [p = 0.06 for 0.5 x 106 MSCs in spheroids vs 
PBS and p = 0.08 for 2.0 x 106 MSCs in spheroids vs PBS; Figure 4C 
and D].
Next, we measured the proinflammatory cytokines locally in the 
distal colon. In our hands, the Th1- and Th17-skewing cytokines 
TNF-α, IFN-ɣ, IL-6, and IL-17a were upregulated in the experimen-
tal colitis compared with normal controls. IFN-ɣ and, to a lesser 
extent, TNF-α were reduced in the distal colons in colitis after treat-
ment with 2.0 x 106 MSCs in spheroids [IFN-ɣ, p < 0.05; Figure 5A 
and B]. In addition, the level of local IL-6 was significantly reduced 
after treatment with MSC spheroids [p = 0.03 for both 0.5 x 106 
and 2.0 x 106 MSCs in spheroids vs PBS; Figure 5C]. IL-17a was, 
although not significantly, also decreased after MSC spheroid treat-
ment compared with PBS [Figure 5D]. IL-2 and IL-4 were not upreg-
ulated compared with healthy control; however, treatment with 2.0 x 
106 MSCs in spheroids significantly reduced both cytokines com-
pared with PBS [Figure 5E and F]. Although MSC spheroid treat-
ment reduced inflammatory responses and thereby alleviated colitis, 
levels of the regulatory cytokine IL-10 were not elevated compared 
with PBS or healthy controls [Figure 5G]. In addition, FoxP3 stain-
ing of the distal colons did not reveal major differences between 
Tregs in the MSC spheroid-treated groups and the PBS-treated mice 
[Figure 5H].
As a measure of mucosal healing, the PGE2 concentration and 
the amount of COX-2 RNA were determined in the homogenates 
of the distal colons. Both PGE2 and COX-2 levels were higher in 
mice with colitis compared with healthy controls at time of sacri-
fice [Figure 6A and B]. Remarkably, the PGE2/COX-2 ratio in the 
mucosa of the colons of the MSC spheroid-treated group showed 
a clear trend to increase towards that of healthy control mice, and 
related to a decrease in disease activity of the intestinal mucosa 
[Figure 6C].
3.3. TNF-α-stimulation of MSC spheroids enhances 
COX-2-dependent PGE2 secretion in vitro
To evaluate if MSC spheroids produce COX-2 dependent PGE2, 
we determined COX-2 RNA in MSC spheroids and PGE2 levels in 
the supernatant, as a proof of principle. In addition, MSC spheroids 
were stimulated with IL-6 or TNF-α at the start of culture, since these 
cytokines were significantly elevated in DSS-induced colitis. Adding 
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IL-6 to MSCs at the start of spheroid induction did not affect the 
expression of COX-2 RNA [Figure  7A]. In concordance with this 
result, PGE2 levels in the supernatants were comparable to those in 
non-stimulated MSC spheroids [Figure 7B]. When TNF-α was added 
at the start of spheroid induction, already 1 day later COX-2 RNA 
expression was increased compared with non- or IL-6-stimulated MSC 
spheroids [Figure 7A]. Moreover, PGE2 levels in the supernatants of 
TNF-α-stimulated MSC spheroid culture were elevated compared 
with non- or IL-6-stimulated MSC spheroids [Figure 7B].
4. Discussion
Recently, MSCs were observed to form aggregates in the perito-










































































































Figure 1. Immunophenotypical characterisation of single cell mesenchymal stromal cells [MSCs] and MSC spheroids. Spheroids were created in 96-well plates 
with 2500 MSCs per well. [A]: Macroscopic picture [left panel], haematoxylin and eosin [HE] staining [central panel], and cleaved caspase-3 staining [right panel] 
of spindle shaped MSCs and MSC spheroids. Magnification x 20. [B]: MSC surface markers CD29, CD44, CD105, CD106, Sca1, [positive] and CD45 [negative] 
as analysed by flow cytometry. [C]: Differentiation into adipocytes [lipid droplets] and osteoblasts [alkaline phosphatase activity and calcium deposit] of MSC 
spheroids [lower panel] was similar to single cell MSCs [upper panel] Magnification x 32.
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colitis.16 In addition, in an experimental myocardial infarction 
model, intravenously injected MSCs were entrapped within the 
lungs where they also formed aggregates that produced TSG-6, 
resulting in less myocardial damage.17 Not only in experimental 
disease models, but also in the healthy state, MSCs tend to spon-
taneously form spheroids.16,21 Therefore, we hypothesised that 
the formation of spheroids is important for MSCs to gain their 
immunosuppressive effects. In this present study, we observed 
that intraluminal treatment with in vitro generated MSC sphe-
roids alleviated moderately-severe DSS-induced colitis but only 
when a high dose of 2.0 x 106 MSCs in spheroids was given. Body 
weight loss and disease activity score at sacrifice were significantly 
reduced after treatment with 2.0 x 106 MSCs in spheroids. The 
percentage of mucosal lesions in the distal colon and endoscopy 
scores were not significantly reduced after MSC spheroid treat-
ment, which resembles human IBD: clinical remission does not 
per definition imply histological and/or endoscopic remission.22,23 
In addition, a retrospective study showed that in patients with 
clinical remission, the presence of mucosal inflammation was not 
associated with more complications or exacerbations during a 
median follow-up of 6.8 years.24
Biochemically, the systemic marker of inflammation SAA was 
elevated after DSS-induced mucosal damage, possibly as a result 
of bacterial invasion. Similarly to other acute phase proteins, SAA 
is mainly produced in the liver. In addition, SAA is also secreted 
into the lumen by colonic epithelial cells, especially in case of 
inflammation and tissue destruction.25,26 Locally, SAA can pro-
mote IL-6 and TNF-α production by macrophages.27,28 Indeed, 
both IL-6 and TNF-α were drastically upregulated after DSS 
administration. Although not significantly, histological evaluation 
demonstrated that the number of macrophages in the mucosa of 
the distal colon was decreased after local MSC spheroid treat-
ment compared with PBS. Moreover, SAA-, IL-6-, and TNF-α lev-
els were reduced. We cannot ensure that IL-6- and TNF-α were 
only produced by macrophages, as dendritic cells and T cells are 










































































































































Figure 2: Intraluminally injected mesenchymal stromal cell [MSC] spheroids alleviate dextran sulphate sodium [DSS]-induced colitis. DSS was introduced in the 
drinking water for 7 days. Mice received 0.5 x 106 or 2.0 x 106 MSCs in spheroids or phosphate-buffered saline [PBS] via enema at dDay 5. Mice were sacrificed 
at Day 10. Data are expressed as mean ± standard error of the mean [SEM]; n = 7–14 per group from two separate experiments. The ‘normal’ group consisted of 
three healthy mice that received 2.0 x 106 MSCs in spheroids. [A]: Body weights were measured daily and expressed as the percentage of body weight at Day 
0; *p = 0.02: 2.0 x 106 MSCs in spheroids vs both PBS and 0.5 x 106 MSCs in spheroids. [B]: Disease-related shortening of the colon. [C]: Macroscopic images 
of representative colons at sacrifice [Day 10]. [D]: Disease activity score based on the presence of loose stool, fecal blood, and macroscopic inflammation 
determined at sacrifice [Day 10]. [E]: Representative histological sections of mouse colons stained with haematoxylin and eosin [HE]. Magnification x 20. [F]: 
Quantification of mucosal lesions defined as parts in the colon without mucosa expressed as a percentage of total colon; n = 3–6 per DSS-group and n = 1 in 
the healthy control group.
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identified as of crucial importance in the innate intestinal immu-
nity. Mice deficient for macrophages or depleted for local gut 
macrophages have less susceptibility to experimental colitis than 
wild type mice.29,30 Moreover, DSS administration to lymphocyte-
deficient mice leads to the development of colitis, indicating that 
macrophages are the key players in establishing DSS-induced 
colitis and that lymphocytes are of less importance therein.31 In 
our experiments, IL-17a was elevated in DSS-induced colitis and 
dose-dependently reduced after intraluminal treatment with MSC 
spheroids. Since secreted IL-17a is reported to regulate migration 
of neutrophils to the place of inflammation,32,33 we examined the 
amount of neutrophils in the distal colons. The amount of neutro-
phils was significantly lower after intraluminal treatment with 2.0 
x 106 MSCs in spheroids.
The exact mechanism of MSC spheroid-mediated attenuation of 
DSS-induced colitis remains partially unclear, as no MSC spheroids 
were found in the colons of treated mice at sacrifice. Both MSCs and 
the supernatants from MSCs are reported to be able to reduce the 
levels of IL-6 and TNF-α secreted by activated macrophages and 
to increase the production of IL-10, resulting in the polarisation 
towards regulatory M2 macrophages.34,35,36 We observed that IL-6 
and TNF-α levels and the number of macrophages in the mucosa 
of the distal colons were reduced, suggesting that in this model 
at time of sacrifice no regulatory macrophages were induced, but 
rather that the number of macrophages was decreased as a sign of 
reduced inflammation after MSC spheroid treatment. In line with 
these results, an increased recruitment of macrophages to the place 
of acute myocardial infarction was found to facilitate cardiac muscle 
repair by MSCs, as no attenuation of disease was observed when 
macrophage recruitment was diminished or MSCs were removed 
after local macrophage infiltration.37 This indicates that the interac-
tion between MSCs and macrophages might be an important factor 
in restoring cardiac function, suggesting that the number of local 
macrophages will be decreased as a sign of attenuated disease when 
cardiac function is restored.
In our hands, IL-10 levels in homogenates of the distal colons 
at sacrifice were similar between MSC spheroids-treated mice and 
mice that received PBS, and not significantly elevated compared 
with healthy controls. Although IL-10 has been described as of 
major importance in the homeostasis of the colonic milieu,38,39 
clinical trials using IL-10 as a treatment for Crohn’s disease have 
failed to show superiority of IL-10 therapy.40 In addition, MSCs co-
cultured in vitro with activated NK cells resulted in reduced levels 
of IL-10.41 On the other hand, when MSCs were co-cultured in 
vitro with dendritic cells, IL-10 production was elevated.42 In DSS-
induced colitis, an abundance of distinct immune cells is present, 
likely resulting in more complex interactions between those cells 
and MSCs compared with the ‘simple’ interaction of MSCs with 
only one type of immune cell in in vitro models. Another possible 
explanation for the lack of IL-10 elevation in MSC spheroid-treated 
mice is the time of sacrifice. It is possible that IL-10 produced by 
either MSCs or Tregs is one of the main factors involved in the 
immunosuppressive process mediated by MSCs directly after injec-
tion. However, we have not sacrificed animals in the first 24-48 h 
after MSC spheroid injection to evaluate this hypothesis. In line 


























































day 5 day 8 day 10 day 12
Figure 3. Endoscopic evaluation of colonic inflammation in mice with dextran sulphate sodium [DSS]-induced colitis. DSS was introduced in the drinking water 
for 7 days. Mice received 2.0 x 106 MSCs in spheroids or phosphate-buffered saline [PBS] via enema at Day 5. Endoscopy was performed at Day 0 before DSS 
introduction and at Days 5, 8, 10, and 12. Mice were sacrificed after the endoscopy at Day 12. Data are expressed as mean ± standard error of the mean [SEM]; 
n = 9–10 per group. [A]: Representative endoscopic images of mice with colitis treated with either 2.0 x 106 MSCs in spheroids or PBS via enema. [B]: Endoscopic 
evaluation of the colonic inflammation using the murine endoscopic index of colitis severity [MEICS] based on the thickening of the colon, changes of the 
vascular pattern, fibrin deposit, granularity of the mucosal surface, and stool consistency.18
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colons at sacrifice, no apparent differences in the number of Tregs 
were found in the distal colons of mice treated with MSC spheroids 
compared with PBS-treated mice.
MSCs are reported to be able to inhibit Th17 cell differentia-
tion and subsequent IL-17a production, which was restored when 
COX-2 was inhibited or PGE2 secretion by MSCs was blocked, sug-
gesting that COX-2 dependent PGE2 is at least one of the paracrine 
factors MSCs produce to gain their immunosuppressive effects.43,44,45 
Whether or not direct cell-to-cell contact between MSCs and 
CD4-positive T cells is needed for the suppression of Th17 cell 
differentiation is doubtful, as previous published papers are not 
consistent. In our present study, however, we do not assume that 
direct contact between IL-17a-producing cells and intraluminally 
injected MSC spheroids is the explanation of the alleviated colitis, 
since even with scrupulous histological evaluation, we have never 
observed the intraluminally injected MSC spheroids in the dam-
aged or healed mucosa. In addition, we generated MSC spheroids 
with GFP-positive MSCs and injected them intraluminally in mice 
with DSS-induced colitis, and these MSCs were not found in the 
mucosa [Supplementary Figure  3]. In addition, for confirmation, 
we performed spheroid tracing experiments with luciferase-trans-
duced MSCs [luc-MSCs] and subsequent bioluminescence imaging 
[see Supplementary data, available at ECCO-JCC online]. Four 
hours after the intraluminal injection of these luc-MSC spheroids, 
hardly any bioluminescence signal was observed when luciferin 
was given intraperitoneally, indicating that the spheroids had 
not engrafted into the colonic mucosa [Supplementary Figure 4A 
and B, see Supplementary data available at ECCO-JCC online]. 
However, when luciferin was given as an enema 4 h after intralu-
minal injection of luc-MSC spheroids, a clear signal was observed 
distally in the colon [Supplementary Figure 4C and D], indicative 
of luminally present luc-MSC spheroids. Further, 16 hours after 
administration of luc-MSC spheroids via enema, no bioluminescent 








































































































0.5x106 spheroids 2.0x106 spheroids
Figure 4. Attenuated colitis is accompanied by reduced systemic and local inflammatory responses. Dextran sulphate sodium [DSS] was introduced in the 
drinking water for 7 days. Mice received 0.5 x 106 or 2.0 x 106 mesenchymal stromal cells [MSCs] in spheroids or phosphate-buffered saline [PBS] via enema at 
Day 5. Mice were sacrificed at Day 10. Data are expressed as mean ± standard error of the mean [SEM]; n = 4–8 per DSS group and n = 2 in the healthy control 
group, that received 2.0 x 106 MSCs in spheroids from two separate experiments. [A]: Measurement of systemic inflammation marker serum amyloid A [SAA]. 
[B]: Myeloperoxidase [MPO] activity was measured in homogenates of the distal colons to evaluate the amount of neutrophils. [C]: Number of macrophages 
per mm in the distal colon; n = 2–3 per DSS-group, n = 1 in the healthy control group. [D]: Representative immunohistological sections of mouse colons stained 
with a F4/80-antibody to reveal macrophages [arrows]. Magnification x 20.
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either intraperitoneally and/or intraluminally. Thus, engraftment of 
the luminally administered MSC spheroids into the mucosa does 
not seem to occur.
COX-2 expression and subsequent production of PGE2 in 
inflamed colons has been identified as an important factor in the 
wound healing process in experimental colitis.46,47 We observed 
that the PGE2/COX-2 ratio was increased in the homogenates 
of the distal colons of colitic mice treated with MSC spheroids 
towards that of healthy control mice, in concert with the decrease 
in disease score at sacrifice. We hypothesise that this is a reflection 
of the healing process initiated by the MSC spheroids, but it is 
certainly not a result of MSC activity within the intestinal mucosa 
simply because these spheroids were not present in the mucosa at 
sacrifice.
Interestingly, supernatants from co-cultures between Th17 
cells and MSCs have been reported to contain elevated PGE2 
levels compared with culture of only CD4-positive T cells or 
MSCs, suggesting that this soluble factor is at least one of the 
key players in the suppressed differentiation.45 In addition, sphe-








































































































































































































Immunohistological staining of FoxP3+ cells
PBS 0.5x106 spheroids 2.0x106 spheroids
Figure 5. Local treatment with mesenchymal stromal cell [MSC] spheroids alters colonic cytokine production. Dextran sulphate sodium [DSS] was introduced in 
the drinking water for 7 days. Mice received 0.5 x 106 or 2.0 x 106 MSCs in spheroids or phosphate-buffered saline [PBS] via enema at Day 5. Mice were sacrificed 
at Day 10. Data are expressed as mean ± standard error of the mean [SEM]; n = 4–8 per DSS-group and n = 2 in the healthy control group that received 2.0 x 106 
MSCs in spheroids from two separate experiments. Cytokine levels of [A] IFN-ɣ, [B] TNF-α, [C] IL-6, and [D] IL-17a were upregulated after colitis induction with 
DSS. No differences between healthy controls and DSS-colitis mice were observed in the cytokine levels of [E] IL-2, [F] IL-4, and [G] IL-10. [H]: Representative 
immunohistological sections of mouse colons stained with a FoxP3-antibody to reveal Tregs [arrows]. Magnification x 20.
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COX-2-dependent PGE2 both in vitro and in vivo.21 In line with 
those results, we observed that MSC spheroids constantly pro-
duced considerable but relatively low levels of COX-2 and PGE2 
in vitro, which increased over time especially when stimulated 
with TNF-α. However, in our in vitro model as proof of princi-
ple, we started with the priming of MSCs at the initiation of the 
aggregation into spheroids, whereas in vivo, if at all, stimulation 
would take place after the formation of spheroids. Interestingly, 
TNF-α induces the expression of COX-2 in colonic epithelial cells 
of patients with IBD and mice with DSS colitis, thereby promot-
ing epithelial wound healing.48,49,50,51 Wound healing was even 
impaired in COX-2-/- mice with DSS-induced colitis as a result 
of an inability to increase colonic PGE2.47 Moreover, intraperi-
toneal administration of PGE2 restored DSS-induced decrease of 
proliferating epithelial cells, indicating a key role for PGE2 in 
mucosal repair.52 We hypothesise that the observed elevated levels 
of TNF-α in the inflamed colons possibly resulted in priming of 
intraluminally injected MSC spheroids to produce high amounts 
of PGE2, subsequently promoting colonic epithelial wound heal-
ing without engraftment of the spheroids within the damaged 
mucosa. Supporting our hypothesis, rectal administration of basic 
fibroblast growth factor ameliorated DSS-induced colitis by acti-
vating COX-2 RNA, which resulted in accelerated mucosal heal-
ing rather than a direct immunosuppressive effect on T cells.46 
However, all these hypotheses are made with utmost caution 
since we did not offer direct evidence that supports an interac-
tion between the intraluminally injected spheroids and TNF-
α and/or the colonic mucosa. In addition, we did not evaluate 
other possible mediators such as TSG-6 and transforming growth 
factor-beta.
Taken together, our results demonstrate that intraluminal injec-
tion of in vitro generated MSC spheroids at least partially attenu-
ates DSS-induced colitis. The dose is important, since only 2.0 x 106 















































































Figure 6. PGE2 and COX-2 RNA in the homogenates of the distal colon. Dextran sulphate sodium [DSS] was introduced in the drinking water for 7 days. Mice 
received 2.0 x 106 mesenchymal stromal cells [MSCs] in spheroids or phosphate-buffered saline [PBS] via enema at Day 5. Mice were sacrificed at Day 10. 
Homogenates were prepared from distal colons. RNA was isolated from the homogenates and cDNA was prepared. COX-2 RNA expression was measured in 
triplicate and normalised to GAPDH and PGE2 levels in duplicate, and corrected for the amount of protein. Disease activity score was based on the presence of 
loose stool, fecal blood, and macroscopic inflammation and determined at sacrifice. Data are expressed as mean ± standard error of the mean [SEM]; n = 4–6 per 
DSS-group and n = 2 in the healthy control group that received 2.0 x 106 MSCs in spheroids from two separate experiments. [A]: Mean concentrations of PGE2 
[ng/mg] and [B]: mean amount of COX-2 RNA relative to GAPDH in the homogenates of the distal colons. [C]: Disease score vs PGE2 concentration corrected for 
the amount of COX-2 RNA present in the homogenates of the distal colons.
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lower disease activity score accompanied by a reduction of systemic 
inflammation, some colonic cytokines, and neutrophils in the distal 
colon.
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